N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide
• 化学式: C17H10N2O5
• 分子量: 322.27
• InChiKey: URUVDCCYSJEGQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• STING INHIBITORS
  申请人：ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

  公开号：EP3502102A1

  公开（公告）日：2019-06-26

  The present invention relates to compounds, compositions for use and methods for the treatment of a STING associated disease, condition, or disorder.

  本发明涉及治疗 STING 相关疾病、病症或紊乱的化合物、用途组合物和方法。
• DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY
  申请人：Ashvattha Therapeutics, Inc.

  公开号：US20210170040A1

  公开（公告）日：2021-06-10

  Dendrimer compositions and methods for the treatment of cancer or autoimmune diseases are described. The compositions include dendrimers complexed or conjugated with one or more active agents for the treatment or alleviation of one or more symptoms of cancer or autoimmune diseases. The dendrimers may include one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10 dendrimers. The active agents may be immunomodulatory agents such as STING agonists, CSF1R inhibitors, PARP inhibitors, VEGFR tyrosine kinase inhibitors, MEK inhibitors, glutaminase inhibitors, TIE II antagonists, and CXCR2 inhibitors, and STING antagonists. Methods of using the dendrimer compositions to treat cancer, bone disease or inflammatory diseases are also provided.
• [EN] USE OF NAD+ PRECURSORS, STING INHIBITORS, AND FXR AGONISTS FOR INHIBITING SARS-COV-2 (COVID-19)-INDUCED CYTOKINE RELEASE<br/>[FR] UTILISATION DE PRÉCURSEURS DE NAD+, D'INHIBITEURS DE STING ET D'AGONISTES DE FXR PERMETTANT D'INHIBER LA LIBÉRATION DE CYTOKINE INDUITE PAR SARS-COV-2 (COVID-19)
  申请人：UNIV GEORGETOWN

  公开号：WO2021237193A1

  公开（公告）日：2021-11-25

  Methods of inhibiting release of one or more cytokines, or inhibiting a cytokine storm, or preventing cytokine release syndrome or a cytokines storm, in a subject infected with severe acquired respiratory syndrome coronavirus 2. The method involves administering to the subject an effective amount of one or more NAD+ precursors, one or more inhibitors of stimulator of interferon genes (STING), one or more famesoid X receptor (FXR) agonists, or a combination thereof. In addition, treatment regimens involving the use of one or more NAD+ precursors, one or more STING inhibitors, one or more FXR agonists, or a combination thereof; and kits comprising pharmaceutical compositions of one or more NAD+ precursors, one or more inhibitors of stimulator of interferon genes, one or more farnesoid X receptor agonists, or combinations thereof.